Literature DB >> 18818881

Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Vijayalakshmi Kunadian1, Cafer Zorkun, Scott P Williams, Leah H Biller, Alexandra M Palmer, Katherine J Ogando, Michelle E Lew, Navin Nethala, William J Gibson, Susan J Marble, Jacqueline L Buros, C Michael Gibson.   

Abstract

Although percutaneous coronary intervention restores optimal epicardial blood flow in most cases, abnormal myocardial perfusion may still persist. This might be as a result of macro and microembolization, neutrophil plugging, vasoconstriction, myocyte contracture, local intracellular and interstitial edema, intramural haemorrhage, and endothelial blistering. Local delivery of intracoronary pharmacotherapy via the coronary arteries may increase local drug concentration several fold, and may improve drug efficacy. Several pharmacological agents such as adenosine, calcium channel blockers, alpha blockers, beta2 receptor activators, vasodilators, antithrombotics, and antiplatelet agents have been used to treat coronary microvascular dysfunction. This article reviews the results of trials of intracoronary pharmacotherapy to date.

Entities:  

Mesh：

Year:  2008        PMID： 18818881     DOI： 10.1007/s11239-008-0276-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  73 in total

Review 1.  Has my patient achieved adequate myocardial reperfusion?

Authors:  C Michael Gibson
Journal:  Circulation       Date:  2003-08-05       Impact factor: 29.690

2.  Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.

Authors:  U Kintscher; K Kappert; G Schmidt; G Doerr; M Grill; B Wollert-Wulf; M Graefe; E Fleck; K Graf
Journal:  Eur J Pharmacol       Date:  2000-02-25       Impact factor: 4.432

3.  [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].

Authors:  Xin-chun Yang; Da-peng Zhang; Le-feng Wang; Li Xu; Yong-gui Ge; Hong-shi Wang; Wei-ming Li; Zhu-hua Ni; Kun Xia; Yong Lian; Yong-li Xue; Li-Xiang Ma
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2007-06

4.  Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase.

Authors:  Robert V Kelly; Eron Crouch; Heather Krumnacher; Mauricio G Cohen; George A Stouffer
Journal:  Catheter Cardiovasc Interv       Date:  2005-11       Impact factor: 2.692

5.  Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine.

Authors:  T A Fischell; A J Carter; M T Foster; K Hempsall; J DeVries; D H Kim; A Kloostra
Journal:  Cathet Cardiovasc Diagn       Date:  1998-12

6.  Characteristics of canine coronary resistance arteries: importance of endothelium.

Authors:  P R Myers; P F Banitt; R Guerra; D G Harrison
Journal:  Am J Physiol       Date:  1989-08

7.  Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion.

Authors:  Amr E Abbas; Stacy D Brewington; Simon R Dixon; Judith A Boura; Cindy L Grines; William W O'Neill
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

8.  Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.

Authors:  Vincenzo Pasceri; Christian Pristipino; Francesco Pelliccia; Antonino Granatelli; Giulio Speciale; Adriana Roncella; Bruno Pironi; Michele Capasso; Giuseppe Richichi
Journal:  Am J Cardiol       Date:  2005-06-01       Impact factor: 2.778

9.  Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study.

Authors:  Chi-Hang Lee; Adrian Low; Bee-Choo Tai; Melissa Co; Mark Y Chan; Jimmy Lim; Yean-Teng Lim; Huay-Cheem Tan
Journal:  Eur Heart J       Date:  2006-11-28       Impact factor: 29.983

10.  Coronary hyperemic dose responses of intracoronary sodium nitroprusside.

Authors:  Walter A Parham; Andre Bouhasin; Jeffrey P Ciaramita; Souheil Khoukaz; Steven C Herrmann; Morton J Kern
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690
View more
  4 in total

Review 1.  Targeting angiogenesis to restore the microcirculation after reperfused MI.

Authors:  Anja M van der Laan; Jan J Piek; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2009-06-16       Impact factor: 32.419

Review 2.  Intramyocardial haemorrhage after acute myocardial infarction.

Authors:  Ryanne P Betgem; Guus A de Waard; Robin Nijveldt; Aernout M Beek; Javier Escaned; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2014-11-18       Impact factor: 32.419

3.  The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Authors:  Sheraz A Nazir; Jamal N Khan; Islam Z Mahmoud; John P Greenwood; Daniel J Blackman; Vijay Kunadian; Martin Been; Keith R Abrams; Robert Wilcox; A A Jennifer Adgey; Gerry P McCann; Anthony H Gershlick
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

4.  Prevention of medical malpractice and disputes through analysis of lawsuits related to coronary angiography and intervention.

Authors:  Cheol Won Hyeon; Won Lee; So Yoon Kim; Ji Yong Park; Su Hwan Shin
Journal:  Korean J Intern Med       Date:  2019-06-14       Impact factor: 2.884
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.